Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0344307 (analgesia)
 28,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 58-year-old man presented with epigastric pain that was refractory to analgesia. Before this, he was well and did not have manifestations of type 1 neurofibromatosis. Endoscopy revealed a 0.5-cm polypoid antral lesion that was snared and removed in total. Histological evaluation showed a submucosal myxoid spindle-cell proliferation. The tumor was arranged in whorls with distinct concentricity. Within the myxoid stroma, occasional eosinophils were present together with a delicate capillary network. There was no cytological atypia, areas of hypercellularity, or necrosis. The lesion was strongly positive for epithelial membrane antigen and also positive for CD34. All other markers including S-100, desmin, and CD117 were negative. The overall morphological and immunophenotypic features of this lesion are in keeping with a myxoid gastric perineurioma. This lesion needs to be separated from an inflammatory fibroid polyp and a gastrointestinal stromal tumor.
 ...
PMID:Myxoid perineurioma presenting as a gastric polyp. 2022 17

Cell transplantation is a potentially powerful approach for the alleviation of chronic pain. The strategy of cell transplantation for the treatment of pain is focused on cell-based analgesia and neural repair. (1) Adrenal medullary chromaffin cells and the PC12 cell line have been used to treat cancer pain and neuropathic pain in both animal models and human cases. As biological or living minipumps, these cells produce and secrete pain-reducing neuroactive substances if administered directly into the spinal subarachnoid space. (2) Cell implantation for pain neurorestorative therapy is a new concept and an emerging research field for pain control along with neural repair. Possible neurorestorative mechanisms include neuroprotective, neurotrophic, neuroreparative, neuroregenerative, neuromodulation, or neuroconstructive interventions, as well as immunomodulation and enhancing the microcirculation. These factors may ultimately restore the damaged or irritated condition of the lesioned nerves. The growing preclinical and clinical data show that neural stem/progenitor cells, olfactory ensheathing cells, mesenchymal stromal cells, and CD34(+) cells have the capacity to manage intractable pain and improve neurological functions. Cell delivery routes include local, intrathecal, or intravascular implants. Although these strategies are still in their infancy phase for pain neurorestoratology, cell-based therapies could open up new avenues for the relief of pain. In this review, these aspects are critically analyzed based on our own investigations. This manuscript is published as part of the International Association of Neurorestoratology (IANR) supplement issue of Cell Transplantation.
 ...
PMID:Cell transplantation as a pain therapy targets both analgesia and neural repair. 2399 23